Eris Tansu, Yanik Ahmet Mert, Demirtas Derya, Yilmaz Asu Fergun, Toptas Tayfur
Hematology, Marmara University School of Medicine, Istanbul, TUR.
Hematology, Marmara University Pendik Training and Research Hospital, Istanbul, TUR.
Cureus. 2023 Mar 16;15(3):e36253. doi: 10.7759/cureus.36253. eCollection 2023 Mar.
Hereditary hyperferritinemia-cataract syndrome (HHCS) is a rare genetic condition characterized by persistent hyperferritinemia (usually ferritin >1,000 ng/mL) without tissue iron overload, with or without early-onset slow-progressing bilateral nuclear cataract. It was first identified as a new genetic disorder in 1995, and since then genetic sequencing studies have been carried out to identify associated mutations in affected families. New mutations around the world are still being reported in the iron-responsive element (IRE) of the L-ferritin gene () to this day. Many clinicians remain unaware of this rare condition. The co-occurrence of mutations and hereditary hemochromatosis (HH) mutations, especially H63D, on the gene has been reported in the literature, which often leads to a diagnosis of HH, missed diagnosis of HHCS, incorrect treatment with phlebotomies and the occurrence of associated iatrogenic iron deficiency anemia. We herein report the case of a 40-year-old woman with spontaneous facial freckling, bilateral cataracts, homozygosity for H63D mutation, iron deficiency anemia, and hyperferritinemia, who has been treated with phlebotomy and iron chelation therapy to no avail. Eleven years after being diagnosed and treated for HH, a reevaluation of her clinical presentation, laboratory results, medical imaging, and family history led to the recognition that her case is explained not by HH, but by an alternative diagnosis, HHCS. Our main objective in this report is to increase clinical awareness about HHCS, an often-unknown differential diagnosis of hyperferritinemia without iron overload, and to prevent adverse medical interventions in HHCS patients.
遗传性高铁蛋白血症-白内障综合征(HHCS)是一种罕见的遗传疾病,其特征为持续性高铁蛋白血症(通常铁蛋白>1000 ng/mL)且无组织铁过载,伴有或不伴有早发性进展缓慢的双侧核性白内障。它于1995年首次被确认为一种新的遗传疾病,自那时起便开展了基因测序研究以确定受影响家族中的相关突变。时至今日,世界各地仍不断有关于L-铁蛋白基因铁反应元件(IRE)新突变的报道。许多临床医生仍未意识到这种罕见疾病。文献中已报道了该基因上 突变与遗传性血色素沉着症(HH)突变,尤其是H63D突变的共同出现,这常导致HH的诊断、HHCS的漏诊、放血疗法的不当治疗以及相关医源性缺铁性贫血的发生。我们在此报告一例40岁女性病例,该患者有面部自发性雀斑、双侧白内障、H63D突变纯合子、缺铁性贫血和高铁蛋白血症,曾接受放血疗法和铁螯合疗法但均无效。在被诊断和治疗HH 11年后,对其临床表现、实验室检查结果、医学影像和家族史进行重新评估后发现,她的病例并非由HH解释,而是另一种诊断——HHCS。我们撰写本报告的主要目的是提高临床医生对HHCS的认识,HHCS是一种常不为人知的无铁过载的高铁蛋白血症鉴别诊断疾病,并防止对HHCS患者进行不良医疗干预。